Fairness opinionsMedical Devices and Supplies2014

Symmetry Medical OEMS Business acquired by Tecomet: fairness opinion by Stifel

Announced August 4, 2014 · One-step merger · Other · DEFM14A filed November 4, 2014
Medical Devices and Supplies OEM / CDMO / Components Sponsor: Genstar Capital
Enterprise value
$450M
EV / LTM EBITDA
8.5x
EBITDA $53.2M · 17% margin
EV / LTM revenue
1.42x
revenue $316M
DCF discount rate
9.0%–11.0%
Exit multiple

Deal terms

ConsiderationOther
Price per share
Premium
Premium basis
StructureOne-step merger
Termination fee$13.5M
Reverse termination fee$27.0M
Go-shopNone
Outside date

Cash merger consideration for SMI common stock plus, in connection with the spin-off, one share of Symmetry Surgical Inc. common stock distributed to SMI stockholders; the per-share cash amount is not stated in the sliced sections.

Implied value per share by method

Selected companies — EV / LTM Net Revenue $7.04 – $10.26
Selected companies — EV / 2014E Net Revenue $7.31 – $10.61
Selected companies — EV / 2015E Net Revenue $6.94 – $10.80
Selected companies — EV / LTM EBITDA $6.77 – $9.36
Selected companies — EV / 2014E EBITDA $8.26 – $9.65
Selected companies — EV / 2015E EBITDA $6.32 – $7.74
Precedent transactions — EV / LTM Net Revenue $3.80 – $7.85
Precedent transactions — EV / LTM EBITDA $4.82 – $7.42
Discounted cash flow $4.79 – $7.49

Ranges as disclosed in the banker’s summary of analyses.

Opinion of Stifel to the target board

Delivered August 3, 2014 · Fee $6.5M ($5.5M contingent on closing), $1.0M on delivery of the opinion

Discounted cash flow assumptions

Discount rate9.0%–11.0%
BasisWACC
Terminal valueExit multiple
Perpetuity growth
Exit multiple
Projection period2H2014E-2018E
Projections usedOEM Solutions Projections provided by SMI management
Implied value per share$4.79–$7.49

Unlevered free cash flows from July 1, 2014 through December 31, 2018 plus terminal enterprise value as of December 31, 2018; implied enterprise values of $346.7 million to $449.6 million.

Selected public companies (3)

Greatbatch, Inc. · ICU Medical, Inc. · Analogic Corporation

MultiplePeer lowPeer medianPeer highRange appliedImplied per share
EV / LTM Net Revenue1.4x1.9x2.0x 1.4x–1.8x $7.04–$10.26
EV / 2014E Net Revenue1.4x2.0x2.0x 1.4x–1.8x $7.31–$10.61
EV / 2015E Net Revenue1.3x1.9x2.0x 1.3x–1.8x $6.94–$10.80
EV / LTM EBITDA8.6x12.7x13.7x 8.5x–10.5x $6.77–$9.36
EV / 2014E EBITDA9.8x10.1x10.3x 9.0x–10.0x $8.26–$9.65
EV / 2015E EBITDA7.7x8.9x9.2x 7.5x–8.5x $6.32–$7.74

Selected precedent transactions (13)

DateTargetAcquirerMultiple
2013-12-19Tecomet, Inc.Genstar Capital, LLC
2013-11-07Paragon Medical, Inc.Beecken Petty O'Keefe & Company
2013-09-13IMDSGolden Equity Investments
2012-07-19Teleflex Incorporated (Ortho OEM Solutions Business)Tecomet, Inc.
2012-02-24Sandvik Medical Solutions Ltd.Orchid MPS Holdings, LLC
2012-01-10Remmele Engineering, IncRTI International Metals, Inc
2011-10-31ATEK Medical GroupVention Medical
2011-07-08Medisize Corp.Phillips Plastics Corp.
2011-06-15Orchid Orthopedic SolutionsAltor Equity Partners
2007-08-30Avail Medical Products, Inc.Flextronics International Ltd.
2005-10-10Accellent Inc.KKR & Co.
2005-04-29The Tech GroupWest Pharmaceutical Services Inc.
2004-04-28Medsource Technologies, Inc.Accellent Inc.
MultipleLowMedianHighRange appliedImplied per share
EV / LTM Net Revenue0.8x1.3x2.7x 1.0x–1.5x $3.80–$7.85
EV / LTM EBITDA7.0x8.3x12.6x 7.0x–9.0x $4.82–$7.42

Other analyses

AnalysisSummaryImplied per share
Solicitation of third-party indications of interestStifel considered the results of its efforts, at SMI's direction, to solicit indications of interest from selected third parties with respect to a merger or other transaction involving the OEM Solutions Business.

$1.0 million payable upon delivery of the Opinion and an additional advisory fee of approximately $5.5 million contingent upon consummation of the Merger; SMI also agreed to indemnify Stifel. Stifel originally engaged August 16, 2012, superseded by letter dated June 3, 2014.

3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
See the Valuation database →

Management projections

Projection yearYear 1Year 2Year 3Year 4CAGR
Revenue$330M$339M$351M$364M3.4%
Revenue growth4.2%3.0%3.5%3.6%
EBITDA$54.0M$54.6M$55.9M$56.5M1.5%
EBITDA growth1.5%1.1%2.4%1.1%
EBITDA margin16%16%16%16%
Implied EV / EBITDA8.3x8.2x8.1x8.0x

Year-1 growth is against LTM at announcement ($316M revenue, $53.2M EBITDA); later years are year over year.

Stifel used the "OEM Solutions Projections" prepared by SMI management covering the second half of calendar 2014 and calendar years 2015 through 2018, including projected 2018 EBITDA used to derive the terminal value. Mean/absolute revenue and EBITDA figures for the projection years are not disclosed in the sliced sections. The projections were not prepared with the expectation of public disclosure.

Process notes

Transaction structured as a spin-off of Symmetry Surgical Inc. to SMI stockholders followed by the cash merger of TecoSym Inc. into SMI, with SMI (the OEM Solutions Business) becoming a wholly-owned subsidiary of Tecomet, a Genstar Capital portfolio company. Stifel's opinion addressed only the fairness of the cash merger consideration for the OEM Solutions Business disposition and expressly did not address the spin-off or Symmetry Surgical. SMI termination fee $13.5 million (or expense reimbursement up to $1.0 million); Tecomet reverse termination fee $27.0 million backstopped by a Genstar equity commitment letter dated August 4, 2014.

Other Medical Devices and Supplies fairness opinions

All Medical Devices and Supplies opinions → · Stifel opinions